Standard Life Aberdeen plc raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 760,737 shares of the medical research company’s stock after purchasing an additional 27,296 shares during the quarter. Standard Life Aberdeen plc owned 0.11% of Amgen worth $132,303,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in AMGN. Toronto Dominion Bank lifted its holdings in shares of Amgen by 11.0% in the 3rd quarter. Toronto Dominion Bank now owns 279,280 shares of the medical research company’s stock worth $52,066,000 after acquiring an additional 27,726 shares during the last quarter. Teacher Retirement System of Texas lifted its holdings in shares of Amgen by 16.5% in the 3rd quarter. Teacher Retirement System of Texas now owns 740,764 shares of the medical research company’s stock worth $138,115,000 after acquiring an additional 104,871 shares during the last quarter. Putnam FL Investment Management Co. bought a new stake in shares of Amgen in the 3rd quarter worth about $447,000. Moody Lynn & Lieberson LLC bought a new stake in shares of Amgen in the 3rd quarter worth about $2,353,000. Finally, Patten Group Inc. lifted its holdings in shares of Amgen by 1,151.5% in the 3rd quarter. Patten Group Inc. now owns 27,859 shares of the medical research company’s stock worth $389,000 after acquiring an additional 25,633 shares during the last quarter. Institutional investors and hedge funds own 79.55% of the company’s stock.
AMGN stock opened at $168.14 on Monday. The stock has a market capitalization of $121,155.33, a P/E ratio of 13.37, a P/E/G ratio of 2.06 and a beta of 1.36. Amgen, Inc. has a 12 month low of $152.16 and a 12 month high of $201.23. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the business earned $2.89 EPS. equities research analysts expect that Amgen, Inc. will post 13.25 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 8th. Shareholders of record on Thursday, May 17th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date is Wednesday, May 16th. Amgen’s dividend payout ratio (DPR) is 41.97%.
Amgen declared that its board has approved a share repurchase plan on Thursday, February 1st that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s board believes its stock is undervalued.
Several equities research analysts have recently issued reports on AMGN shares. Vetr lowered shares of Amgen from a “buy” rating to a “hold” rating and set a $184.25 target price for the company. in a report on Wednesday, January 3rd. Royal Bank of Canada restated a “hold” rating and issued a $189.00 target price on shares of Amgen in a report on Wednesday, January 24th. Barclays lowered their target price on shares of Amgen from $190.00 to $180.00 and set an “equal weight” rating for the company in a report on Thursday. ValuEngine lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Monday, April 2nd. Finally, Piper Jaffray restated a “buy” rating on shares of Amgen in a report on Tuesday, January 2nd. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the stock. Amgen presently has a consensus rating of “Hold” and a consensus price target of $190.57.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction dated Friday, March 16th. The shares were sold at an average price of $189.75, for a total transaction of $289,368.75. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 4,575 shares of company stock worth $838,064 in the last three months. Insiders own 0.19% of the company’s stock.
WARNING: “Standard Life Aberdeen plc Grows Holdings in Amgen, Inc. (AMGN)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/standard-life-aberdeen-plc-grows-holdings-in-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.